An Open-Label, Randomized, Multicenter, Phase II Study of MDX-060 in Combination With Gemcitabine and Gemcitabine Monotherapy in Patients With Relapsed or Refractory Hodgkin's Disease.
Phase of Trial: Phase II
Latest Information Update: 27 Nov 2012
At a glance
- Drugs Iratumumab (Primary) ; Dexamethasone; Gemcitabine
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 03 Nov 2009 Actual number of patients (74) added as reported by ClinicalTrials.gov.
- 03 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Jun 2009 Planned end date changed from 1 Oct 2008 to 1 Oct 2009 as reported by ClinicalTrials.gov.